publication . Other literature type . Article . 2001

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

Peter Trainer;
Open Access
  • Published: 01 Nov 2001
  • Publisher: Elsevier BV
"Background Pegvisomant is a new growth hormone receptor antagonist that improves symptoms and normalises insulin-like growth factor-1 (IGF-1) in a high proportion of patients with acromegaly treated for up to 12 weeks. We assessed the effects of pegvisomant in 160 patients with acromegaly treated for an average of 425 days. Methods Treatment efficacy was assessed by measuring changes in tumour volume by magnetic resonance imaging, and serum growth hormone and IGF-1 concentrations in 152 patients who received pegvisomant by daily subcutaneous injection for up to 18 months. The safety analysis included 160 patients some of whom received weekly injections and are ...
free text keywords: General Medicine
Download fromView all 3 versions
The Lancet
Provider: UnpayWall
UNC Dataverse
Other literature type . 2001
Provider: Datacite
The Lancet
Article . 2002
Provider: Crossref
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue